{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:25:50Z","timestamp":1783635950579,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2026,1,10]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SMARCA4-deficient neoplasms are aggressive tumours typically arising in the thoracic region, often responding to immunotherapy despite poor prognosis. Although rare, these tumours can also occur in the gastrointestinal tract, including the oesophagus. Given the potential for misdiagnosis, particularly when tumours present with undifferentiated morphology, this study aimed to identify key diagnostic features of SMARCA4-deficient undifferentiated carcinoma of the oesophagus (SMARCA4-deficient UC) and highlight the clinical importance of accurate diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and method<\/jats:title>\n                    <jats:p>A retrospective review of 36 oesophageal carcinoma cases with undifferentiated histology was conducted following institutional review board approval. All cases underwent BRG1 (SMARCA4) immunohistochemical (IHC) staining, with complete loss of nuclear BRG1 expression used to identify SMARCA4-deficiency. Histopathologic evaluation and relevant clinical data were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SMARCA4 deficiency was identified in 22 of 36\u2009cases (61%). There were no significant differences in tumour morphology, size, association with Barrett\u2019s, or clinical presentation between SMARCA4-deficient and SMARCA4-intact cases. However, significant differences in immunophenotype were observed, particularly regarding keratin and synaptophysin expression. Notably, eight SMARCA4-deficient cases were initially misclassified as neuroendocrine carcinoma due to synaptophysin positivity. Despite low tumour mutation burden, patients with SMARCA4-deficient UC showed improved survival when treated with immunotherapy. Additionally, three SMARCA4-deficient tumours exhibited areas of differentiated carcinoma adjacent to undifferentiated components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Frequent synaptophysin expression in SMARCA4-deficient UC of the oesophagus can lead to diagnostic confusion with neuroendocrine carcinomas, resulting in potential mismanagement. BRG1 IHC should be incorporated in the diagnostic workup of poorly differentiated oesophageal tumours to ensure accurate classification and guide effective treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2025-210396","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:20:27Z","timestamp":1769538027000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Frequent synaptophysin expression in SMARCA4-deficient undifferentiated carcinoma of the oesophagus: a diagnostic pitfall with therapeutic implications"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-5513","authenticated-orcid":false,"given":"Shaimaa","family":"Elzamly","sequence":"first","affiliation":[{"name":"Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M","family":"Al-Attar","sequence":"additional","affiliation":[{"name":"Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa W","family":"Taggart","sequence":"additional","affiliation":[{"name":"Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai C","family":"Foo","sequence":"additional","affiliation":[{"name":"Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A","family":"Ajani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Maru","sequence":"additional","affiliation":[{"name":"Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyali","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026031905050583000_79.4.229.1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2628"},{"key":"2026031905050583000_79.4.229.2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2018.01.009","article-title":"The SWI\/SNF complex subunit genes: Their functions, variations, and links to risk and survival outcomes in human cancers","volume":"123","author":"Savas","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026031905050583000_79.4.229.3","doi-asserted-by":"crossref","first-page":"113855","DOI":"10.1016\/j.celrep.2024.113855","article-title":"SWI\/SNF-dependent genes are defined by their chromatin landscape","volume":"43","author":"Basurto-Cayuela","year":"2024","journal-title":"Cell Rep"},{"key":"2026031905050583000_79.4.229.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0357-3"},{"key":"2026031905050583000_79.4.229.5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cncy.22709","article-title":"Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology","volume":"131","author":"Kezlarian","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"2026031905050583000_79.4.229.6","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.61"},{"key":"2026031905050583000_79.4.229.7","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report","volume":"10","author":"Takada","year":"2019","journal-title":"Thorac Cancer"},{"key":"2026031905050583000_79.4.229.8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0433"},{"key":"2026031905050583000_79.4.229.9","unstructured":"Editorial. B . WHO Classification of Tumors: Digestive Tumors. Lyon, France: International Agency for Research on Cancer Publications, 2019."},{"key":"2026031905050583000_79.4.229.10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.humpath.2014.11.021","article-title":"Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases","volume":"46","author":"Singhi","year":"2015","journal-title":"Hum Pathol"},{"key":"2026031905050583000_79.4.229.11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/PAS.0000000000000554","article-title":"SWI\/SNF Complex-deficient Undifferentiated\/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2","volume":"40","author":"Agaimy","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2026031905050583000_79.4.229.12","doi-asserted-by":"crossref","DOI":"10.21037\/tgh-23-84","article-title":"Esophageal carcinoma with SMARCA4 mutation: a narrative review for this rare entity","volume":"9","author":"Xu","year":"2024","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2026031905050583000_79.4.229.13","unstructured":"Bergsland EG , Benson A , Berman Z , et al . NCCN clinical practice guidelines in oncology (nccn guidelines) for neuroendocrine and adrenal tumors v.1.2024."},{"key":"2026031905050583000_79.4.229.14","doi-asserted-by":"crossref","first-page":"154692","DOI":"10.1016\/j.prp.2023.154692","article-title":"Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges","volume":"248","author":"Cui","year":"2023","journal-title":"Pathol Res Pract"},{"key":"2026031905050583000_79.4.229.15","doi-asserted-by":"crossref","first-page":"217282","DOI":"10.1016\/j.canlet.2024.217282","article-title":"SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling","volume":"605","author":"Field","year":"2024","journal-title":"Cancer Lett"},{"key":"2026031905050583000_79.4.229.16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/PAS.0000000000001836","article-title":"SWI\/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies","volume":"46","author":"Chang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2026031905050583000_79.4.229.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1825"},{"key":"2026031905050583000_79.4.229.18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/PAS.0000000000001599","article-title":"SMARCA4\/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction","volume":"45","author":"Horton","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"2026031905050583000_79.4.229.19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/10668969231171941","article-title":"Undifferentiated Carcinoma of Esophagus with SMARCA4 Deletion Expressing Synaptophysin: A Potential Diagnostic Pitfall","volume":"32","author":"Cui","year":"2024","journal-title":"Int J Surg Pathol"},{"key":"2026031905050583000_79.4.229.20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00428-021-03156-9","article-title":"Mesenchymal\/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI\/SNF-deficient tumors","volume":"479","author":"Kasajima","year":"2021","journal-title":"Virchows Arch"},{"key":"2026031905050583000_79.4.229.21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/10668969211047982","article-title":"Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression","volume":"30","author":"Mao","year":"2022","journal-title":"Int J Surg Pathol"},{"key":"2026031905050583000_79.4.229.22","doi-asserted-by":"crossref","first-page":"100183","DOI":"10.1016\/j.modpat.2023.100183","article-title":"SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach","volume":"36","author":"Neil","year":"2023","journal-title":"Mod Pathol"},{"key":"2026031905050583000_79.4.229.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6425-3","article-title":"Loss of the SWI\/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma","volume":"20","author":"Schallenberg","year":"2020","journal-title":"BMC Cancer"},{"key":"2026031905050583000_79.4.229.24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/cancers16071300","article-title":"SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel","volume":"16","author":"Yamashita","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026031905050583000_79.4.229.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026031905050583000_79.4.229.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz134"},{"key":"2026031905050583000_79.4.229.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3797"},{"key":"2026031905050583000_79.4.229.28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/annonc\/mdz160","article-title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","volume":"30","author":"Henon","year":"2019","journal-title":"Ann Oncol"},{"key":"2026031905050583000_79.4.229.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06958-9","article-title":"CDK4\/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary","volume":"10","author":"Xue","year":"2019","journal-title":"Nat Commun"},{"key":"2026031905050583000_79.4.229.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08380-1"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2025-210396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:05:41Z","timestamp":1773921941000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2025-210396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,19]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jcp-2025-210396"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2025-210396","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}